Research progress of immune checkpoint inhibitor-induced enterocolitis
10.3760/cma.j.cn101480-20210409-00027
- VernacularTitle:免疫抑制剂检查点相关肠炎的诊治进展
- Author:
Wei WANG
1
;
Min ZHANG
;
Baili CHEN
Author Information
1. 中山大学附属第六医院消化内科，广州 510655
- Publication Type:Journal Article
- Keywords:
Immune checkpoint inhibitors;
Enterocolitis;
Clinical manifestation;
Treatment
- From:
Chinese Journal of Inflammatory Bowel Diseases
2021;05(3):237-241
- CountryChina
- Language:Chinese
-
Abstract:
Immune checkpoint inhibitors (ICI) have been widely used in the treatment of a variety of malignancies. ICI may induce immune-related adverse events (irAEs) . irAEs could affect multiple organs in the body, among which gastrointestinal adverse reactions are the most common ones, mainly involved the colon and small intestine, often accompanied by diarrhea symptoms, which is called immune checkpoint inhibitor-induced enterocolitis. This article mainly introduces the pathogenesis, risk factors, clinical manifestations and management of ICI-induced enterocolitis, in order to better identify ICI-related gastrointestinal adverse reactions and improve its effectiveness of treatment.
